Ivermectin is an anti-parasitic agent that has shown promise against the virus in vitro. Its potential mechanism of action (MoA) in COVID-19, is poorly understood. Explore the live graph.
Acalabrutinib is an anti-cancer medicine (tyrosine kinase inhibitor) showing promise in early studies. Its potential mechanism of action (MoA) is poorly understood. If understood better, more anti-cancer drugs can be rationalized against COVID-19. MoA elements include genes, and pathways that may explain the MoA of the drug in particularly ameliorating cytokine storm-related features in COVID-19. … Read More
Vitamin D supplementation has been shown to protect against SARS-COV-2 infection, and could be particularly helpful for patients that exhibit shortage of vitamin D (e.g. seniors, immunocompromised patients) leading to complications such as cardiovascular comorbidities. This graph explains the mechanism of action of vitamin D in COVID-19 via key genes implicated. Explore the live graph.
Azithromycin is being tested in COVID-19 patients. Although it is a potent antibiotic, in the COVID-19 setting, it likely acts as an anti-inflammatory agent. Its exact MoA in the disease, however, remains to be elucidated. Explore the live graph.
Dexamethasone is a widely-used and safe steroid that has been studied in the context of treating viral respiratory disorders, and is THE FIRST drug that has been shown to reduce mortality of patients with severe COVID-19. Explore the live graph.